These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1022 related articles for article (PubMed ID: 33933106)

  • 1. Serum GFAP and NfL as disease severity and prognostic biomarkers in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder.
    Schindler P; Grittner U; Oechtering J; Leppert D; Siebert N; Duchow AS; Oertel FC; Asseyer S; Kuchling J; Zimmermann HG; Brandt AU; Benkert P; Reindl M; Jarius S; Paul F; Bellmann-Strobl J; Kuhle J; Ruprecht K
    J Neuroinflammation; 2021 May; 18(1):105. PubMed ID: 33933106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
    Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
    Front Immunol; 2021; 12():647618. PubMed ID: 33796113
    [No Abstract]   [Full Text] [Related]  

  • 3. Serum neurofilament light chain and glial fibrillary acidic protein in AQP4-IgG-seropositive neuromyelitis optica spectrum disorders and multiple sclerosis: A cohort study.
    Liu C; Lu Y; Wang J; Chang Y; Wang Y; Chen C; Liu Z; Kermode AG; Zhang Y; Qiu W
    J Neurochem; 2021 Dec; 159(5):913-922. PubMed ID: 34278578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum glial fibrillary acidic protein correlates with retinal structural damage in aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
    Lin TY; Schindler P; Grittner U; Oertel FC; Lu A; Motamedi S; Yadav SK; Duchow AS; Jarius S; Kuhle J; Benkert P; Brandt AU; Bellmann-Strobl J; Schmitz-Hübsch T; Paul F; Ruprecht K; Zimmermann HG
    Mult Scler Relat Disord; 2022 Nov; 67():104100. PubMed ID: 36049341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD.
    Watanabe M; Nakamura Y; Michalak Z; Isobe N; Barro C; Leppert D; Matsushita T; Hayashi F; Yamasaki R; Kuhle J; Kira JI
    Neurology; 2019 Sep; 93(13):e1299-e1311. PubMed ID: 31471502
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decipher potential biomarkers of diagnosis and disease activity for NMOSD with AQP4 using LC-MS/MS and Simoa.
    Wang J; Wang J; Xie W; Liu J; Feng J; Wei W; Li M; Wu L; Wang C; Li R
    Int Immunopharmacol; 2023 Mar; 116():109761. PubMed ID: 36709595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood sphingolipid as a novel biomarker in patients with neuromyelitis optica spectrum disorder.
    Kim H; Kim HJ; So J; Kim JY; Jung HJ; Kim S; Seo D; Kim HJ; Song HE; Lim YM; Yoo HJ; Lee EJ
    Mult Scler Relat Disord; 2024 May; 85():105551. PubMed ID: 38564996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum biomarkers in myelin oligodendrocyte glycoprotein antibody-associated disease.
    Kim H; Lee EJ; Kim S; Choi LK; Kim K; Kim HW; Kim KK; Lim YM
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32184342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of serum markers with optical coherence tomography angiography for evaluating neuromyelitis optica spectrum disorders and multiple sclerosis.
    Liu C; Zhou W; Sun X; Zhang X; Xiao H; Yang H; Lin H; Lu Y; Liu Z; Qiu W; Kermode AG; Yang X; Wang Y
    Mult Scler Relat Disord; 2024 May; 85():105478. PubMed ID: 38457885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder.
    Aktas O; Hartung HP; Smith MA; Rees WA; Fujihara K; Paul F; Marignier R; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Cutter G; She D; Gunsior M; Cimbora D; Katz E; Cree BA;
    J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):757-768. PubMed ID: 37221052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal change of serum NfL as disease activity biomarker candidate in MOGAD: A descriptive cohort study.
    Schindler P; Bellmann-Strobl J; Kuhle J; Wildemann B; Jarius S; Paul F; Ruprecht K
    Mult Scler Relat Disord; 2024 Aug; 88():105729. PubMed ID: 38901371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
    Aktas O; Smith MA; Rees WA; Bennett JL; She D; Katz E; Cree BAC;
    Ann Neurol; 2021 May; 89(5):895-910. PubMed ID: 33724534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the Presence of Interattack Astrocyte Damage in Neuromyelitis Optica Spectrum Disorder: Longitudinal Analysis of Serum Glial Fibrillary Acidic Protein.
    Hyun JW; Kim Y; Kim SY; Lee MY; Kim SH; Kim HJ
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33846219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glial fibrillary acidic protein as a biomarker in neuromyelitis optica spectrum disorder: a current review.
    Schindler P; Aktas O; Ringelstein M; Wildemann B; Jarius S; Paul F; Ruprecht K
    Expert Rev Clin Immunol; 2023 Jan; 19(1):71-91. PubMed ID: 36378751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High serum neurofilament levels among Chinese patients with aquaporin-4-IgG-seropositive neuromyelitis optica spectrum disorders.
    Liu C; Zhao L; Fan P; Ko H; Au C; Ng A; Au L; Wong A; Kermode AG; Mok V; Yan Y; Qiu W; Lau AY
    J Clin Neurosci; 2021 Jan; 83():108-111. PubMed ID: 33317883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients.
    Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S
    J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum Biomarker Profiles Discriminate AQP4 Seropositive and Double Seronegative Neuromyelitis Optica Spectrum Disorder.
    Carta S; Dinoto A; Capobianco M; Valentino P; Montarolo F; Sala A; Reindl M; Lo Re M; Chiodega V; Branger P; Audoin B; Aboab J; Papeix C; Collongues N; Kerschen P; Zephir H; Créange A; Bourre B; Schanda K; Flanagan EP; Redenbaugh V; Villacieros-Álvarez J; Arrambide G; Cobo-Calvo A; Ferrari S; Marignier R; Mariotto S
    Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):e200188. PubMed ID: 38134369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum neurofilament light chain predicts spinal cord atrophy in neuromyelitis optica spectrum disorder.
    Li Y; Liu Y; Zhao W; An X; Zhang F; Zhang TX; Liu Y; Du C; Zeng P; Yuan M; Zhang N; Zhang C
    J Neuroimmunol; 2023 Nov; 384():578218. PubMed ID: 37801952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders.
    Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS
    Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytokines and Tissue Damage Biomarkers in First-Onset Neuromyelitis Optica Spectrum Disorders: Significance of Interleukin-6.
    Wei Y; Chang H; Li X; Wang H; Du L; Zhou H; Xu W; Ma Y; Yin L; Zhang X
    Neuroimmunomodulation; 2018; 25(4):215-224. PubMed ID: 30544111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.